본문으로
MMadical AI Use
공급사 보고공급사

Quantitative assist for immunohistochemistry scoring

이 언어의 본문은 아직 없어 영어로 보여 줍니다.

Vendors including PathAI and Ibex offer algorithms that estimate staining extent, such as a Ki-67 or PD-L1 percentage, on a digitized slide. A pathologist checks the region and the number before it enters the report. This card does not restate concordance percentages, which are assay-specific and easy to over-read. The signed score remains a pathology result, not a model result.

임상 현장

Immunohistochemistry sign-out in a digital pathology lab, where the stain already has a clinical scoring scheme the tumor board expects.

도구와 공급사

  • PathAI
  • Ibex

출처가 보고한 내용

No concordance figure is copied here. Treat vendor white papers as vendor-reported until an independent study matches the assay you actually run.

출처

PathAI · 2025년 2월 1일 · 연도 2025

색인 추가일 2026년 7월 2일

출처 열기

태그

  • 병리
  • 사람이 개입
  • 컴퓨터 비전

교육과 시장 탐색용 항목. 의학 조언도 추천도 아닙니다.

병리

규제

Adjunct detection on prostate biopsy whole-slide images

Paige Prostate marks a location on a digitized prostate biopsy slide that the model ranks as the most suspicious for cancer, after the pathologist’s own first look. FDA authorized it in 2021 as an adjunct. The output is not the diagnosis. The pathologist still signs out, using the full clinical context and any extra stains they choose to order.

Paige Prostate · Paige FullFocus

뉴스 · 2021사례 읽기

영상과 영상의학

규제

Autonomous diabetic retinopathy screening in primary care

IDx-DR, now marketed as LumineticsCore by Digital Diagnostics, was authorized to screen adults with diabetes for more-than-mild diabetic retinopathy without an eye specialist reading the photo first. A primary care team captures images on a specified retinal camera and the software returns a refer-or-rescreen result. It is not a complete eye examination. Pregnancy and several existing retinal conditions sit outside the labeled use.

LumineticsCore (IDx-DR) · Digital Diagnostics · Topcon NW400

뉴스 · 2018사례 읽기

영상과 영상의학

논문

AI-supported reading in the MASAI mammography trial

The MASAI trial in Sweden randomly assigned screening mammograms to AI-supported reading or standard double reading without AI. Transpara scored each exam and routed lower scores to a single reader and the highest score to double reading, with detection marks available on higher-risk exams. This card quotes the prespecified interim safety analysis, not a claim that every screening program should switch.

Transpara 1.7.0 · ScreenPoint Medical

논문 · 2023사례 읽기
후원

이 색인의 임상 독자에게 닿습니다.

후원 안내